Post by
guarantor1 on May 18, 2021 8:20pm
HaemoneticsTEG doing well
Under Hospital business, the Hemostasis Management product line saw strong growth in the past few quarters. The product line continued to be benefit from strong capital equipment sales in the United States and sales of TEG cartridges in Europe. In January, the FDA issued a new guidance on viscoelastic testing mentioning the use of TEG devices for improved patient care during the pandemic. Considering the pandemic scenario and the higher need to treat COVID-19 patients, we expect these devices to have registered robust sales during the fiscal fourth-quarter as well, thus adding to overall growth.
from May 12
https://finance.yahoo.com/news/haemonetics-hae-report-q4-earnings-102210108.html
Comment by
guarantor1 on May 19, 2021 6:38pm
From Q4 Haemonetics discussion, May 14 Hemostasis Management revenue was up 19% in the fourth quarter and 9% in fiscal '21. North America, our largest market, showed sequential growth throughout the first nine months of the year. And despite a spike in COVID cases early in the fourth quarter, the business exited in a strong position, including additional penetration into new accounts
Comment by
guarantor1 on May 19, 2021 6:48pm
Okay !!! This is simply conjecture from a very hopeful and optimistic Long Time Ibex holder, But.... Haemonetics Hemostasis Management doing well= Haemonetics TEG doing well= Heparinase sales from Ibex to Haemonetics doing well. Which I think represents maybe 50% of Ibex's revenue. Correct me if you think I am wrong.
Comment by
guarantor1 on May 19, 2021 7:32pm
And if we get any kind of a sales push From Hemonetics, For the next year, or two, Before Diamine Oxidase comes. Then we might have a Big Story